Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes.

Clin Pharmacol · 2016 · PMC4847607 · PMID 27186083

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Changes in blood pressure were small and significant in empagliflozin 10 mg/d subjects but did not reach statistical significance at 78 weeks in the empagliflozin 25 mg/d group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.